SB-121

Lactobacillus reuteri with Sephadex and maltose · Scioto Biosciences, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for SB-121, covering 2024-03-25 to 2024-03-25. Get the full timeline:

Most recent: Clinical Trial Update: 28-Day Daily-dose Crossover Study of the Safety and Tolerability of SB-121 (Lactobacillus Reuteri With Sephadex® and Maltose) in Subjects, Ages 15 to 45 Years, Diagnosed With Autistic Disorder [Phase 1]

See pricing